Organogenesis’ (ORGO) “Buy” Rating Reiterated at BTIG Research

BTIG Research reissued their buy rating on shares of Organogenesis (NASDAQ:ORGO) in a research note issued to investors on Friday morning, Marketbeat Ratings reports. BTIG Research currently has a $9.00 target price on the stock.

A number of other research firms have also weighed in on ORGO. Weiss Ratings reiterated a “sell (d+)” rating on shares of Organogenesis in a research report on Monday, December 22nd. Wall Street Zen raised shares of Organogenesis from a “hold” rating to a “strong-buy” rating in a report on Saturday, November 8th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $8.00.

Organogenesis Stock Performance

Shares of ORGO stock opened at $5.28 on Friday. The stock’s 50-day moving average is $5.05 and its two-hundred day moving average is $4.62. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.88 and a current ratio of 3.32. Organogenesis has a 1 year low of $2.61 and a 1 year high of $7.08. The firm has a market cap of $670.08 million, a price-to-earnings ratio of -44.00 and a beta of 1.47.

Organogenesis (NASDAQ:ORGO) last announced its earnings results on Thursday, November 6th. The company reported $0.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.07 by $0.11. Organogenesis had a negative net margin of 1.30% and a positive return on equity of 4.01%. The business had revenue of $150.86 million for the quarter, compared to analyst estimates of $134.10 million. Analysts predict that Organogenesis will post -0.07 earnings per share for the current year.

Insider Activity

In related news, Director Glenn H. Nussdorf sold 200,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $5.14, for a total value of $1,028,000.00. Following the completion of the transaction, the director directly owned 2,565,591 shares of the company’s stock, valued at $13,187,137.74. This trade represents a 7.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last ninety days, insiders have sold 500,000 shares of company stock valued at $2,620,120. Company insiders own 33.00% of the company’s stock.

Institutional Trading of Organogenesis

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. PharVision Advisers LLC acquired a new position in Organogenesis in the 3rd quarter valued at about $155,000. Quarry LP acquired a new stake in shares of Organogenesis during the 3rd quarter worth about $25,000. First Light Asset Management LLC grew its holdings in shares of Organogenesis by 10.6% during the third quarter. First Light Asset Management LLC now owns 7,497,911 shares of the company’s stock worth $31,641,000 after buying an additional 720,748 shares in the last quarter. Bank of America Corp DE raised its position in shares of Organogenesis by 27.2% in the third quarter. Bank of America Corp DE now owns 611,685 shares of the company’s stock valued at $2,581,000 after buying an additional 130,875 shares during the last quarter. Finally, Creative Planning raised its position in shares of Organogenesis by 8.2% in the third quarter. Creative Planning now owns 38,279 shares of the company’s stock valued at $162,000 after buying an additional 2,887 shares during the last quarter. Hedge funds and other institutional investors own 49.57% of the company’s stock.

Organogenesis Company Profile

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.